Christopher Moore

9PUBLICATIONS
83CO-AUTHORS
Molecular targetsCancer genetics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Jun 08, 2026
KRAS Inhibitor Induced Cancer Cell Death Enhances Sensitivity to Immune-Mediated Bystander Killing of Drug-Resistant Subclones.

|Nov 01, 2024
Spatial multiplex analysis of lung cancer reveals that regulatory T cells attenuate KRAS-G12C inhibitor-induced immune responses.

Megan Cole, Panayiotis Anastasiou, Claudia Lee

|Sep 25, 2024
Combining RAS(ON) G12C-selective inhibitor with SHP2 inhibition sensitises lung tumours to immune checkpoint blockade.

Panayiotis Anastasiou, Christopher Moore, Sareena Rana

|Apr 18, 2024
CRISPR-Cas9 Screening Identifies KRAS-Induced COX2 as a Driver of Immunotherapy Resistance in Lung Cancer.

Jesse Boumelha, Andrea de Castro, Nourdine Bah

|Aug 05, 2022
An Immunogenic Model of KRAS-Mutant Lung Cancer Enables Evaluation of Targeted Therapy and Immunotherapy Combinations.

Jesse Boumelha, Sophie de Carné Trécesson, Emily K Law

|Jul 20, 2022
Therapeutic KRAS<sup>G12C</sup> inhibition drives effective interferon-mediated antitumor immunity in immunogenic lung cancers.

Edurne Mugarza, Febe van Maldegem, Jesse Boumelha

Pageof 2

Frequent Collaborators

9 joint publications

Julian Downward

8 joint publications

Miriam Molina-Arcas

4 joint publications

Sophie de Carné Trécesson

3 joint publications

Philip East